Loading...
•
Jun 30, 2021
Vera Q2 2021 Earnings Report
Reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.
Key Takeaways
Vera Therapeutics reported a net loss of $3.4 million, or a net loss per diluted share of $0.33, and cash and cash equivalents of $91.6 million.
Initiated patient enrollment for the dose-ranging Phase 2b ORIGIN trial, evaluating atacicept in IgAN patients.
Expanded the management team with the appointment of Sean Grant as Chief Financial Officer.
Reported $91.6 million in cash and cash equivalents as of June 30, 2021, including net proceeds from the company’s initial public offering.
Net loss was $3.4 million, or $0.33 per diluted share.
Forward Guidance
The press release contains forward-looking statements regarding the results of Vera’s Phase 2b ORIGIN trial.
Positive Outlook
- statements regarding the results of Vera’s Phase 2b ORIGIN trial
- plans
- will
- anticipates
- goal
Challenges Ahead
- risks and uncertainties associated with Vera’s business in general
- the impact of the COVID-19 pandemic
- the other risks described in Vera’s filings with the Securities and Exchange Commission.
- Actual results could differ materially from those anticipated
- involve assumptions that may never materialize or may prove to be incorrect
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...